References
- Kara Ö, Zarakolu P, Aşçioğlu S, et al. Epidemiology and emerging resistance in bacterial bloodstream infections in patients with hematologic malignancies. Infect Dis (Lond). 2015;47:686–693.
- Hughes WT, Armstrong D, Bodey GP, et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis. 1997;25:551–573.
- Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730–751.
- Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:56–93.
- Masaoka T. Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary. Clin Infect Dis. 2004;39:S49–S52.
- de Naurois J, Novitzky-Basso I, Gill MJ, et al. Management of febrile neutropenia: ESMO clinical practice guidelines. Ann Oncol. 2010;21:252–256.
- Gaytan-Martinez J, Mateos-Garcia E, Sanchez-Cortes E, et al. Microbiological findings in febrile neutropenia. Arch Med Res. 2000;31:388–392.
- Engelhart S, Glasmacher A, Exner M, et al. Surveillance for nosocomial infections and fever of unknown origin among adult hematology-oncology patients. Infect Control Hosp Epidemiol. 2002;23:244–248.
- Urabe A. Clinical features of the neutropenic host: definitions and initial evaluation. Clin Infect Dis. 2004;39:53–55.
- Viscoli C, Varnier O, Machetti M. Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification. Clin Infect Dis. 2005;40:240–245.